Table 2.
Industrial efforts towards clinical applications of RNAi
| Company | Partners | Indications |
|---|---|---|
| Acuity Pharmaceuticals | Alcon | VEGF in AMD, diabetic retinopathy. |
| Alnylam | Merck, Mayo Clinic, Medtronics, Novartis | AMD, diabetic retinopathy and diabetic macular edema; cystic fibrosis; respiratory syncytial virus (RSV); spinal cord injury; pandemic flu; other programs at Huntington's, Parkinson's diseases and neuropathic pain. |
| Atugen | Sanofi Aventis, Quark Biotech | AMD, prostate, lung, pancreas, hepatocellular carcinoma. |
| Benitec | Center for Biomedicine and Genetics | HIV and AIDS-related lymphoma with siRNA, using lenti virus; Hepatitis-C. |
| CombiMatrix | Diagnostics, early drug development | |
| CytRx | MGH, Imperial college, London | Obesity, type 2 diabetes, CMV, ALS |
| Genta | Technology platform, cancer targets | |
| Intradigm | VEGF in colon cancer and ocular neovascularization, SARS coronavirus. | |
| International Therapeutics | City of Hope National Medical Center and Beckman Research Institute | HIV |
| Isis | Lilly, GSK, Novartis, Oncogenex, OSI, Rosetta, Pfizer, ALS Association | Type 2 diabetes, homozygous familial hypercholesterolemia, amyotrophic lateral sclerosis, ulcerative colitis, irritable bowel disease, Crohn's disease, asthma, multiple sclerosis, prostate cancer and other solid tumors, psoriasis, age related macular degeneration and diabetic retinopathy. |
| Sirna Therapeutics | Allergan, Targeted Genetics, GSK | VEGF in AMD, Huntington's disease, Respiratory diseases (COPD) |
| ToleroTech | Transplant rejection and autoimmune diseases |